Analyst Price Targets — BHC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 7, 2026 12:19 pm | Les Sulewski | Truist Financial | $8.00 | $7.63 | TheFly | Bausch Health price target raised to $8 from $7 at Truist |
| December 8, 2025 9:25 pm | Glen Santangelo | Barclays | $8.00 | $6.82 | TheFly | Bausch Health initiated with an Equal Weight at Barclays |
| October 23, 2024 11:34 am | Douglas Miehm | RBC Capital | $10.00 | $8.07 | TheFly | Bausch Health price target raised to $10 from $8.50 at RBC Capital |
| July 25, 2024 9:08 am | Les Sulewski | Truist Financial | $7.00 | $5.69 | TheFly | Bausch Health price target lowered to $7 from $8 at Truist |
| July 10, 2024 8:13 am | Michael Freeman | Raymond James | $8.00 | $7.19 | TheFly | Bausch initiated with Market Perform on Xifaxan risk at Raymond James |
| April 29, 2024 7:39 am | David Amsellem | Piper Sandler | $9.00 | $8.78 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $9 at Piper Sandler |
| April 23, 2024 6:08 am | Doug Miehm | RBC Capital | $11.00 | $8.45 | StreetInsider | Bausch Health Companies (BHC) PT Lowered to $11 at RBC Capital |
| April 11, 2024 11:29 am | Glen Santangelo | Jefferies | $16.00 | $9.28 | StreetInsider | Jefferies on BHC (BHC): 'We see this as an extremely positive outcome for BHC and removes a key barrier to executing the spin' |
| April 5, 2024 6:16 am | Doug Miehm | RBC Capital | $12.00 | $10.05 | StreetInsider | Bausch Health Companies (BHC) PT Raised to $12 at RBC Capital |
| September 9, 2022 6:34 am | — | Piper Sandler | $6.00 | $6.70 | Benzinga | Piper Sandler Maintains Neutral on Bausch Health Companies, Lowers Price Target to $6 |
Latest News for BHC
LAVAL, QC, Feb. 23, 2026 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in medical aesthetics, today announced the launch of the Clear + Brilliant® Touch laser in Canada. The device was approved by Health Canada on May 20, 2025, marking an important milestone as demand for non‑invasive skin rejuvenation treatments…
IRWD has the edge over BHC with high Linzess demand and upbeat 2026 revenue outlook offsetting pipeline and pricing risks.
Bausch + Lomb delivered 7% constant currency Q4 revenue growth and 27% adjusted EBITDA growth, reinforcing strong operating leverage. I maintain my Buy rating on BLCO, citing robust revenue momentum, promising product pipelines, and a path toward improved profitability and valuation. BLCO targets 5–7% annual revenue growth through 2028, driven by innovation in contact lenses, dry eye therapies, and premium…
Bausch stock slips as Q4 EPS misses despite 9% revenue growth, strong Salix and Bausch + Lomb gains, and an upbeat 2026 sales outlook.
How Bausch Health's Turnaround Progressed In Q4 2025
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BHC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.